Thrombolytic stroke therapy - Past, present, and future

被引：51

作者：

Zivin, JA ^{[1
]}

机构：

[1] Univ Calif San Diego, Dept Neurosci, La Jolla, CA 92093 USA

来源：

NEUROLOGY | 1999年 / 53卷 / 01期

关键词：

D O I：

10.1212/WNL.53.1.14

中图分类号：

R74 [神经病学与精神病学];

学科分类号：

摘要：

Until 1995, treatment of strokes consisted exclusively of efforts to prevent recurrence. Proof that tissue plasminogen activator is useful for acute management is changing the approach to stroke patients. The development process has been difficult and the current treatment recommendations have been controversial. Recent successful clinical trials lend additional credence to these concepts. Future treatment strategies will probably include combinations of thrombolytics and neuroprotectants of various types. However, the need to initiate treatment rapidly after stroke onset is likely to continue.

引用

页码：14 / 19

页数：6

共 30 条

[1]

Abe T, 1981, BLOOD VESSELS, V12, P342

[2]

Andre C, 1998, J Stroke Cerebrovasc Dis, V7, P255, DOI 10.1016/S1052-3057(98)80035-9

[3] MONOCLONAL-ANTIBODIES PREVENTING LEUKOCYTE ACTIVATION REDUCE EXPERIMENTAL NEUROLOGIC INJURY AND ENHANCE EFFICACY OF THROMBOLYTIC THERAPY [J].

BOWES, MP ;

ROTHLEIN, R ;

FAGAN, SC ;

ZIVIN, JA .

NEUROLOGY, 1995, 45 (04) :815-819

[4] Generalized efficacy of t-PA for acute stroke - Subgroup analysis of the NINDS t-PA stroke trial [J].

Brott, T ;

Broderick, J ;

Kothari, R ;

ODonoghue, M ;

Barsan, W ;

Tomsick, T ;

Spilker, J ;

Miller, R ;

Sauerbeck, L ;

Farrell, J ;

Kelly, J ;

Perkins, T ;

Miller, R ;

McDonald, T ;

Rorick, M ;

Hickey, C ;

Armitage, J ;

Perry, C ;

Thalinger, K ;

Rhude, R ;

Schill, J ;

Becker, PS ;

Heath, RS ;

Adams, D ;

Reed, R ;

Klei, M ;

Hughes, A ;

Anthony, J ;

Baudendistel, D ;

Zadicoff, C ;

Rymer, M ;

Bettinger, I ;

Laubinger, P ;

Schmerler, M ;

Meiros, G ;

Lyden, P ;

Dunford, J ;

Zivin, J ;

Rapp, K ;

Babcock, T ;

Daum, P ;

Persona, D ;

Brody, M ;

Jackson, C ;

Lewis, S ;

Liss, J ;

Mahdavi, Z ;

Rothrock, J ;

Tom, T ;

Zweifler, R .

STROKE, 1997, 28 (11) :2119-2125

[5] URGENT THERAPY FOR STROKE .1. PILOT-STUDY OF TISSUE PLASMINOGEN-ACTIVATOR ADMINISTERED WITHIN 90 MINUTES [J].

BROTT, TG ;

HALEY, EC ;

LEVY, DE ;

BARSAN, W ;

BRODERICK, J ;

SHEPPARD, GL ;

SPILKER, J ;

KONGABLE, GL ;

MASSEY, S ;

REED, R ;

MARLER, JR .

STROKE, 1992, 23 (05) :632-640

[6]

COLLEN D, 1984, J PHARMACOL EXP THER, V231, P146

[7] PROACT: A phase II randomized trial of recombinant pro-urokinase by direct arterial delivery in acute middle cerebral artery stroke [J].

del Zoppo, GJ ;

Higashida, RT ;

Furlan, AJ ;

Pessin, MS ;

Rowley, HA ;

Gent, M .

STROKE, 1998, 29 (01) :4-11

[8] RECOMBINANT TISSUE PLASMINOGEN-ACTIVATOR IN ACUTE THROMBOTIC AND EMBOLIC STROKE [J].

DELZOPPO, GJ ;

POECK, K ;

PESSIN, MS ;

WOLPERT, SM ;

FURLAN, AJ ;

FERBERT, A ;

ALBERTS, MJ ;

ZIVIN, JA ;

WECHSLER, L ;

BUSSE, O ;

GREENLEE, R ;

BRASS, L ;

MOHR, JP ;

FELDMANN, E ;

HACKE, W ;

KASE, CS ;

BILLER, J ;

GRESS, D ;

OTIS, SM .

ANNALS OF NEUROLOGY, 1992, 32 (01) :78-86

[9] Streptokinase for acute ischemic stroke with relationship to time of administration [J].

Donnan, GA ;

Davis, SM ;

Chambers, BR ;

Gates, PC ;

Hankey, GJ ;

McNeil, JJ ;

Rosen, D ;

StewartWynne, EG ;

Tuck, RR .

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1996, 276 (12) :961-966

[10] Cost-effectiveness of tissue plasminogen activator for acute ischemic stroke [J].

Fagan, SC ;

Morgenstern, LB ;

Petitta, A ;

Ward, RE ;

Tilley, BC ;

Marler, JR ;

Levine, SR ;

Broderick, JP ;

Kwiatkowski, TG ;

Frankel, M ;

Brott, TG ;

Walker, MD .

NEUROLOGY, 1998, 50 (04) :883-890

← 1 2 3 →